The Motley Fool

Neil Woodford completely ditched this FTSE 100 stock, but I’d happily buy it today!

Since the FTSE 100 index plunged below 5,000 on 23 March, share prices have largely only gone upwards. Since late March, the FTSE 100 rose near-relentlessly, climbing almost every week. By 7 June, the index had soared 30% above its 2020 low.

The FTSE 100’s worst week since March

But the week just gone was the worst for almost three months, leaving complacent investors reeling. A four-day losing streak from Monday, snapped by a 0.5% recovery on Friday, saw the FTSE 100 dive 5.8% in the week. The FTSE 250 index fell even further, down 6.4%.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

We should forgive Mr Market for having a minor meltdown. On Thursday, when the FTSE 100 dived 4%, we discovered that the UK economy had shrunk 20.4% in locked-down April. Blimey!

This FTSE 100 winner is immune to coronavirus

Clearly, we need to get Covid-19 under control, so British workers can rebuild our shattered economy. But the recovery’s shape and speed will determine how quickly corporate earnings recover to support higher share prices.

Meanwhile, some solid companies have proved completely immune to the coronavirus. One of these fortress FTSE 100 firms is ‘big pharma’ player GlaxoSmithKline (LSE: GSK).

Neil Woodford ditched GSK, then blew up his funds

I’m a cheerleader for GSK, because I’ve been an admirer of this British powerhouse since I was a teenager. I’ve owned this FTSE 100 share for most of the past 30 years. Also, two family members have clocked up 50+ years between them working at GSK.

Former star fund manager Neil Woodford was once a big fan and major shareholder of GSK too. The FTSE 100 star was a core holding of Woodford’s once-successful income funds. Then Woodford sold his entire GSK holding (worth £1.2bn) in May 2017. Since then, his eponymous funds have spectacularly crashed to earth. Oops.

GSK is changing dramatically

GSK is actually three global businesses in one: researching, developing and manufacturing pharmaceuticals, vaccines and consumer-healthcare products. After a major reshuffle, GSK is now ranked at #4 in the FTSE 100. At 1,599p a share, its market value is £80.2bn.

As a mega-cap company, GSK is all big numbers. It employs 100,000 people worldwide and dates back to 1715. The FTSE 100 firm is a huge spender on research and development, boosting investment to £4.3bn in 2019 alone.

In 2019, its sales hit £33bn and pre-tax profit leapt to £6.2bn, up 29% from £4.8bn in 2018. In April, GSK revealed first-quarter sales up 19% year-on-year.

A decent dividend and future growth?

Many investors regard GSK as a safe, boring FTSE 100 share paying a high dividend (currently yielding 5%). The shares trade on a price-to-earnings ratio of under 15 and the 80p yearly dividend is covered 1.34 times by earnings. Solid and safe, but dull.

In 2020, GSK shares bottomed at 1,328p (16 March) and peaked at 1,587p (24 January). Despite Covid-19, the shares are up 1% over 12 months. But what if GSK becomes a more exciting growth share, as in its go-go years?

Today, it has 37 new medicines and 15 new vaccines in development. Furthermore, ViiV Healthcare (GSK’s HIV/AIDS joint venture) has Cabotegravir. This HIV-prevention injection is so efficacious that clinical trials were stopped three years early. Astonishing.

In short, combining a low rating and high dividend yield with potential growth, GSK shares are my #1 FTSE 100 stock for patient investors.

A top income share that boasts a reliably defensive business model… plus a current forecast dividend yield of 4.2% to boot!

With global markets in turmoil as the coronavirus pandemic tightens its grip, turning to shares to generate income isn’t as simple as it used to be…

As the realities of ‘life under lockdown’ begin to bite, many of the stock market’s ‘go-to’ high-yielding companies have either taken an axe to their dividend pay-outs… or worse, opted to suspended them altogether – for the near-term at least.

With so many blue-chip and mid-cap companies scrambling to hoard cash right now, where are we income investors to turn for decent yields?

Fortunately, The Motley Fool is here to help…

Our analyst has unearthed what he believes could be a very attractive option for income- seeking investors – a company that, in his view, boasts a ‘reliably defensive’ business model, combined with a current forecast dividend yield of 4.2% to boot!*

But here’s the really exciting part…

This business even has form in riding out this kind of situation, too… having previously increased sales and profits back in 2008 and 2009 when the world was gripped in the deepest economic crisis since the Great Depression.

*Please be aware that dividends are variable and not guaranteed.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Income Share… free of charge!

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.